Application No.: 10/069,772

Inventor: FEUSSNER et al.

Reply to Office Action of 03 January 2007

Docket No.: 50669

REMARKS/ARGUMENTS

Claims 1, 4-10, 12-14, 24-28 and 30 are pending. Claims 27 and 30 are amended.

Support for the amendment to claim 27 can be found at least in claim 1 and claim 27 as

originally filed. Claim 30 has been amended in accordance with the Examiner's suggestions in

the 03 January 2007 Office Action.

Entry and consideration of the instant claim amendments after final is respectfully

requested as the instant claim amendments place the application in condition for allowance

and/or in better format for Appeal and/or further limit issues which may be raised on appeal.

Applicant respectfully submits that the instant amendments were not previously

submitted as the issues addressed by the amendments were only raised for the first time in the Final Action. Accordingly, Applicant could not have made the requisite claim amendments

obviating the issues at an earlier stage in the proceedings. Additionally, the instant claim

amendments merely obviate the issues newly raised by the Examiner and do not change the

amendments merely obviate the issues newly raised by the Examiner and do not change the scope of the claims or add new matter which would necessitate further substantial examination

and/or search by the Examiner.

In view thereof, favorable action is respectfully requested.

Election/Restriction

The Examiner has withdrawn claim 27 asserting that the claim is drawn to a non-elected

invention. Applicant amended claim 27 to contain proper antecedent basis to claim 1 and to

better clarify the claim. Thus, because claim 27 depends directly from the isolated nucleic acid

sequence which encodes a polypeptide of claim 1, the restriction requirement should be

withdrawn and the claim rejoined.

Further, because claim 27 depends from claim 1, and claim 1 is allowable, claim 27

should be allowable. Favorable action is solicited.

Additionally, Applicant respectfully requests rejoinder of withdrawn claims 2-3, 15-17, 18, 20 and 22. As a National Stage of a PCT, the instant application falls under PCT Rule 13 in

regard to restriction requirements. The Examiner is directed specifically to Rule 13.4 which

Page 7 of 9

Application No.: 10/069,772 Inventor: FEUSSNER et al.

Reply to Office Action of 03 January 2007

Docket No.: 50669

states:

Subject to Rule 13.1, it shall be permitted to include in the same international application a reasonable number of dependent claims, claiming specific forms of the invention claimed in an independent claim, even where the features of any

dependent claim could be considered as constituting in themselves an invention.

Accordingly, because the instant claims fulfill the unity of invention requirement of Rule 13.1, as evidenced by the allowability of claim 1, claims 2-3, 15-17, 18, 20 and 22 should be

rejoined. Favorable action is solicited.

Claim objections

Claim 30 has been amended according to the Examiner's suggestions and thus, the

objections are moot.

Remarks regarding 35 USC 112 ¶2

The Examiner asserts that claims 29 and 30 are allegedly indefinite. While neither

agreeing with the Examiner's reasons for or correctness of the rejection, Applicant canceled claim 29 and the rejection for this claim is moot. Further, Applicant's amended claim 30 now

recites "nucleic" instead of "nuclei" and the rejection for this claim is also moot.

Page 8 of 9

Application No.: 10/069,772 Inventor: FEUSSNER et al.

Reply to Office Action of 03 January 2007

Docket No.: 50669

Conclusion

Applicant respectfully submits that the present application is in condition for allowance, which action is courteously requested. Please charge any shortage in fees due in connection with the filing of this paper to Deposit Account 14.1437. Please credit any excess fees to such account.

Respectfully submitted,

NOVAK DRUCE & QUIGG, LLP

Todd R. Samelman Registration No.: 53,547

Customer No.: 26474 1300 Eye St. N.W. 400 East Tower

Washington, D.C. 20005 Phone: (202) 659-0100 Fax: (202) 659-0105